Wednesday, June 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “modified”

433 pharma patents match "modified" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 433
Index total 30,257
Page 6 / 19

Quick answer

This filtered view shows 433 pharmaceutical patents matching "modified" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

433 results for “modified” · 30,257 patents in full index Clear search

  1. US 10982203

    Modified factor IX polypeptides and uses thereof

    Catalyst Biosciences, Inc. · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted
  2. US 10954501

    Nucleic acid encoding modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use

    Catalyst Biosciences, Inc. · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted
  3. US 10954498

    Modified cascade ribonucleoproteins and uses thereof

    Caribou Biosciences, Inc. · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted
  4. US 10941402

    Chemically modified single-stranded RNA-editing oligonucleotides

    ProQR Therapeutics II B.V. · Granted Mar 9, 2021 · Expires Mar 4, 2041

    granted
  5. US 10913957

    Genetically modified MSC and therapeutic methods

    The Regents of the University of California · Granted Feb 9, 2021 · Expires Feb 4, 2041

    granted
  6. US 10905709

    Modified antisense oligomers for exon inclusion in spinal muscular atrophy

    Sarepta Therapeutics, Inc. · Granted Feb 2, 2021 · Expires Jan 28, 2041

    granted
  7. US 10881086

    Genetically modified mouse whose genome comprises a humanized CD274 gene

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 5, 2021 · Expires Dec 31, 2040

    granted
  8. US 10875885

    β-d-2′-deoxy-2′-α-fluoro-2′-β-c-substituted-2-modified-n6-substituted purine nucleotides for HCV treatment

    Atea Pharmaceuticals, Inc. · Granted Dec 29, 2020 · Expires Dec 24, 2040

    granted
  9. US 10870673

    β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

    Atea Pharmaceuticals, Inc. · Granted Dec 22, 2020 · Expires Dec 17, 2040

    granted
  10. US 10870672

    β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

    Atea Pharmaceuticals, Inc. · Granted Dec 22, 2020 · Expires Dec 17, 2040

    granted
  11. US 10864266

    Modified lipopolysaccharide glycoform and method of use

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Dec 15, 2020 · Expires Dec 10, 2040

    granted
  12. US 10858633

    Method for producing foot-and-mouth disease virus (FMDV) viral proteins utilizing a modified FMDV 3C protease

    The Government of the United States of America, as represented by the Secretary of Homeland Security · Granted Dec 8, 2020 · Expires Dec 3, 2040

    granted
  13. US 10844098

    Method for preparing bacterial polysaccharide-modified recombinant fusion protein and use of the protein

    Institute of Biotechnology, Academy of Military Medical Sciences, China · Granted Nov 24, 2020 · Expires Nov 19, 2040

    granted
  14. US 10842743

    Modified hyaluronic acid hydrogels and proteins for the time-controlled release of biologic agents

    The Regents of the University of California · Granted Nov 24, 2020 · Expires Nov 19, 2040

    granted
  15. US 10835593

    Modified anthrax toxin protective antigen

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Nov 17, 2020 · Expires Nov 12, 2040

    granted
  16. US 10815266

    β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

    Atea Pharmaceuticals, Inc. · Granted Oct 27, 2020 · Expires Oct 22, 2040

    granted
  17. US 10808230

    Selection methods for genetically-modified T cells

    The Board of Regents of the University of Texas System · Granted Oct 20, 2020 · Expires Oct 15, 2040

    granted
  18. US 10800833

    Co-stimulatory domains for use in genetically-modified cells

    Precision BioSciences, Inc. · Granted Oct 13, 2020 · Expires Oct 8, 2040

    granted
  19. US 10785968

    Genetically modified non-human animals and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 29, 2020 · Expires Sep 24, 2040

    granted
  20. US 10781435

    Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use

    Catalyst Biosciences, Inc. · Granted Sep 22, 2020 · Expires Sep 17, 2040

    granted
  21. US 10760078

    Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups

    Sarepta Therapeutics, Inc. · Granted Sep 1, 2020 · Expires Aug 27, 2040

    granted
  22. US 10730837

    Modified amino acids

    Sutro Biopharma, Inc. · Granted Aug 4, 2020 · Expires Jul 30, 2040

    granted
  23. US 10722459

    Methods for producing carboxylate ligand modified ferric iron hydroxide colloids and related compositions and uses

    United Kingdom Research and Innovation · Granted Jul 28, 2020 · Expires Jul 23, 2040

    granted
  24. US 10717720

    Modified compound of andrographolide

    Medshine Discovery Inc. · Granted Jul 21, 2020 · Expires Jul 16, 2040

    granted